Investigating the discernible and distinct effects of platinum‑based chemotherapy regimens for metastatic triple‑negative breast cancer on time to progression

Khalaf,Daniel; Hilton,John F.; Clemons,Mark; Azoulay,Laurent; Yin,Hui; Vandermeer,Lisa; Dent,Susan; Hopkins,Sean; Bouganim,Nathaniel

doi:10.3892/ol.2014.1782

2014-March Volume 7 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

2014-March Volume 7 Issue 3

Full Size Image

Article

Investigating the discernible and distinct effects of platinum‑based chemotherapy regimens for metastatic triple‑negative breast cancer on time to progression

Authors:
- Daniel Khalaf
- John F. Hilton
- Mark Clemons
- Laurent Azoulay
- Hui Yin
- Lisa Vandermeer
- Susan Dent
- Sean Hopkins
- Nathaniel Bouganim
View Affiliations / Copyright

Affiliations: Division of Hematology‑Oncology, University of Montreal - Notre-Dame Hospital, Montreal, QC H2L 4M1, Canada, Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada, Department of Oncology, Royal Victoria Hospital, McGill University, Montreal, QC H3A 1A1, Canada, Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada, Department of Pharmacy, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada
Pages: 866-870
|
Published online on: January 7, 2014

https://doi.org/10.3892/ol.2014.1782
Expand metrics +

Abstract

Platinum‑based chemotherapy regimens are frequently used in patients with triple‑negative breast cancer (TNBC). The aim of the current study was to assess whether or not platinum‑based chemotherapy is associated with an increased time to progression when compared with non‑platinum‑based regimens in TNBC and non‑TNBC. A retrospective analysis was conducted within a cohort of patients with metastatic breast cancer who received platinum‑based chemotherapy at a single institution. Data were collected for up to three lines of treatment for metastatic disease. Time to progression was determined for platinum‑based chemotherapy and non‑platinum‑based regimens for each line of treatment. Adjusted hazard ratios (HRs), together with 95% confidence intervals (CIs) were estimated comparing the time to progression associated with the use of platinum‑based chemotherapy versus non‑platinum‑based regimens. A total of 159 patients were included in the analysis, with 58 diagnosed with TNBC. Among the patients with TNBC, compared with non‑platinum‑based chemotherapy, no correlation was identified between platinum‑based chemotherapy and an improved time to progression [first line: HR, 0.97 (95% CI, 0.40‑2.35); second line: HR, 0.91 (95% CI, 0.42‑2.01); and third line: HR, 2.83 (95% CI, 0.73‑11.03)]. By contrast, patients with non‑TNBC appeared to improve with non‑platinum‑based chemotherapy [first line: HR, 2.57 (95% CI, 1.11‑5.99); second line: HR, 1.91 (95% CI, 1.00‑3.63); and third line: HR, 1.08 (95% CI, 0.53‑2.18)]. Although the present study was limited by the sample size and its observational nature, the results indicated that platinum‑based chemotherapy does not offer a discernible or distinct advantage compared with standard regimens in patients with TNBC, and is perhaps less efficacious in patients with non‑TNBC.

View Figures

View References

1	Clemons M, Leahy M, Valle J, et al: Review of recent trials of chemotherapy for advanced breast cancer: studies excluding taxanes. Eur J Cancer. 33:2171–2182. 1997. View Article : Google Scholar : PubMed/NCBI
2	Tassone P, Tagliaferri P, Perricelli A, et al: BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 88:1285–1291. 2003. View Article : Google Scholar : PubMed/NCBI
3	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI
4	Santana-Davila R and Perez EA: Treatment options for patients with triple-negative breast cancer. J Hematol Oncol. 3:422010. View Article : Google Scholar : PubMed/NCBI
5	Byrski T, Gronwald J, Huzarski T, et al: Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 28:375–379. 2010. View Article : Google Scholar
6	Staudacher L, Cottu PH, Dieras V, et al: Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol. 22:848–856. 2011. View Article : Google Scholar : PubMed/NCBI
7	Silver DP, Richardson AL, Eklund AC, et al: Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 28:1145–1153. 2010. View Article : Google Scholar : PubMed/NCBI
8	Baselga J, Gomez P, Awada A, et al: The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression free survival (PFS) in metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II study (Bali-1). In: Abstract Book of the 35th ESMO congress; 2010 Oct 8–12; Milan, Italy. Annals of Oncology. 21. pp. viii1–viii96
9	Isakoff SJ: Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 16:53–61. 2010. View Article : Google Scholar : PubMed/NCBI
10	Kassam F, Enright K, Dent R, et al: Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 9:29–33. 2009. View Article : Google Scholar
11	Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 28:2784–2795. 2010. View Article : Google Scholar
12	Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
13	O’Shaughnessy J, Osborne C, Pippen JE, et al: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 364:205–214. 2011.PubMed/NCBI
14	Carey LA, Rugo HS, Marcom PK, et al: TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol. 26(Suppl 15): 10092008.
15	Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
16	Robert NJ, Dieras V, Glaspy J, et al: RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 29:1252–1260. 2011. View Article : Google Scholar
17	Sledge GW Jr, Loehrer PJ Sr, Roth BJ and Einhorn LH: Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol. 6:1811–1814. 1988.PubMed/NCBI
18	Kolarić K and Roth A: Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol. 11:108–112. 1983.
19	Perez EA: Carboplatin in combination therapy for metastatic breast cancer. Oncologist. 9:518–527. 2004. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Investigating the discernible and distinct effects of platinum‑based chemotherapy regimens for metastatic triple‑negative breast cancer on time to progression

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles